Abstract
Strains of Staphylococcus aureus and coagulase-negative Staphylococcus with different antibiotic susceptibilities were selected to be the test targets of four synthesized compounds of N-aryl-4-guanidinomethylbenzoates and N-aryl-4-guanidinobenzamides. Minimum inhibitory concentrations of the four compounds showed comparable results to 13 commercial antibiotics. Metabolomics analysis based on GC–MS indicated that the four compounds shared the similar antimicrobial mechanism with clindamycin, but K–B disc diffusion tests implied that their exact binding site might be different from clindamycin or the current macrolide resistance mechanisms had no effect on the actions of synthesized compounds. The major effects of the studied compounds on the intercellular metabolites of S. aureus were the increased intracellular d-glucose, proline, phosphate and propanoic acid concentrations. This study proved metabolomics analysis was a promising tool in antibiotic mechanism research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
